AEON gets FDA Type 2b feedback on ABP-450 biosimilar pathway for BOTOX
FDA meeting minutes support a potentially narrower clinical program, with an IND for a pharmacodynamic study planned for the fourth quarter of 2026.
SEC filing
Latest
3 stories
Yesterday
Wednesday, August 12
AEON Biopharma reports Q2 2026 results, cites new financing and FDA meeting on ABP-450
The company reported cash of $3.4 million as of June 30, 2026, plus a July financing that it says extends its runway into early 2027 as it awaits further FDA feedback on its Botox biosimilar.
SEC filing
Wednesday, July 15
AEON Biopharma closes $13.75 million offering with attached milestone warrants
The biosimilar developer priced and closed an underwritten stock and warrant sale, netting $12.2 million with up to $29.6 million more possible if warrants are exercised.
SEC filing (3)